ABC	Accelerated blood clearance
AKT	v-Akt murine thymoma viral oncogene homolog
ALP	Alkaline phosphatase
AMPK	AMP-activated protein kinase
AuNPs	Gold nanoparticles
BBB	Blood–brain barrier
BOIN (TITE-BOIN)	Time-to-event Bayesian Optimal Interval (dose-escalation design)
Cmax	Maximum plasma concentration
CMC	Carboxymethyl chitosan
CNS	Central nervous system
CRISPR	Clustered Regularly Interspaced Short Palindromic Repeats
EGCG	Epigallocatechin gallate
EMA	European Medicines Agency
EPR	Enhanced permeability and retention
EVs	Extracellular vesicles
FDA	Food and Drug Administration
FA	Folic acid
GNA	Gambogenic acid
GMP	Good manufacturing practice
GSH	Glutathione
HAP	Hydroxyapatite
LNPs	Lipid nanoparticles (for nucleic-acid delivery)
LPHNs	Lipid–polymer hybrid nanoparticles
mRNA	Messenger RNA
mTOR	Mechanistic target of rapamycin
MTD	Maximum tolerated dose
MEW	Melt electrospinning writing
MSNs	Mesoporous silica nanoparticles
NIR	Near-infrared
NLCs	Nanostructured lipid carriers
OS	Overall survival
PCL	Poly(ε-caprolactone)
PBLG	Poly(γ-benzyl-L-glutamate)
PBPK	Physiologically based pharmacokinetic
PEG	Polyethylene glycol
PHPMA	Poly(hydroxypropyl methacrylamide)
PDI	Polydispersity index
PD	Pharmacodynamics
PK	Pharmacokinetics
PLGA	Poly(lactic-co-glycolic acid)
PFS	Progression-free survival
ROS	Reactive oxygen species
RBC	Red blood cell
RBCM-NPs	Red blood cell membrane–coated nanoparticles
RBC-EVs	Red blood cell–derived extracellular vesicles
RC-Lips	Red blood cell–mimicking liposomes
RP2D	Recommended Phase II dose
RT	Radiotherapy
TMZ	Temozolomide
TPGS	d-α-Tocopheryl polyethylene glycol 1000 succinate
SLN/SLNs	Solid lipid nanoparticle(s)
t½ (t1/2)	Terminal half-life
Tmax	Time to Cmax
YAP	Yes-associated protein